Ashley Preston, Ph.D.
Senior Vice President, Head of Regulatory Affairs and Quality Assurance
Ashley Preston, Ph.D., is senior vice president, head of regulatory affairs and quality assurance at BlossomHill Therapeutics. He has over 20 years of experience in the biopharma industry, building and leading global teams in regulatory affairs, medical writing and GxP quality assurance.
Most recently, Dr. Preston was senior vice president, global regulatory affairs, quality and operational excellence at Syros Pharmaceuticals Inc., where he established and led the regulatory affairs, quality assurance and medical writing teams at Syros, supporting multiple clinical-stage assets in both hematologic malignancies and solid tumors. Dr. Preston also led the operational excellence function to provide innovative solutions and best practices to optimize the organization’s effectiveness while growing and delivering on the development pipeline.
Prior to Syros, Dr. Preston held various senior roles in regulatory affairs at both small and large biopharma companies including Merck KGaA, Takeda, H3 Biomedicine and GlaxoSmithKline in the US, Singapore, and Australia. His global regulatory expertise spans multiple regions, countries, and therapeutic areas, as well as the full drug development spectrum from pre-IND through NDA to post-marketing.
Dr. Preston holds a Bachelor of Science with honors in pharmacology from Monash University in Melbourne and a Ph.D. in pharmacology from RMIT University in Melbourne. He is a member of the Regulatory Affairs Professionals Society (RAPS), previously sat on the RAPS Pan-Asia Advisory Committee (PAAC), and has RAPS US Regulatory Affairs Certification (RAC US, 2008).